当前位置:
X-MOL 学术
›
Blood Cancer J.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status.
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2019-05-15 , DOI: 10.1038/s41408-019-0207-7 Lauren K Shea 1 , Kazuhito Honjo 1 , David T Redden 2 , Edlue Tabengwa 1 , Ran Li 1 , Fu-Jun Li 1 , Mikhail Shakhmatov 1 , Nicholas Chiorazzi 3 , Randall S Davis 1, 4, 5, 6
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2019-05-15 , DOI: 10.1038/s41408-019-0207-7 Lauren K Shea 1 , Kazuhito Honjo 1 , David T Redden 2 , Edlue Tabengwa 1 , Ran Li 1 , Fu-Jun Li 1 , Mikhail Shakhmatov 1 , Nicholas Chiorazzi 3 , Randall S Davis 1, 4, 5, 6
Affiliation
Article
中文翻译:
Fc受体样2(FCRL2)是低风险CLL的新型标志物,可根据IGHV突变状态改善预后。
文章
更新日期:2019-11-18
中文翻译:
Fc受体样2(FCRL2)是低风险CLL的新型标志物,可根据IGHV突变状态改善预后。
文章